[HTML][HTML] The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis
F Wu, J Song, Z Zhao, X Huang, J Mao, J Tu… - Mathematical …, 2019 - aimspress.com
BackgroundAn increasing number of patients with advanced non-small cell lung cancer
(NSCLC) have a poor prognosis and develop progressive disease after receiving …
(NSCLC) have a poor prognosis and develop progressive disease after receiving …
The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis
FZ Wu, JJ Song, ZW Zhao, XF Huang… - Mathematical …, 2019 - pubmed.ncbi.nlm.nih.gov
Background: An increasing number of patients with advanced non-small cell lung cancer
(NSCLC) have a poor prognosis and develop progressive disease after receiving …
(NSCLC) have a poor prognosis and develop progressive disease after receiving …
The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis.
FZ Wu, JJ Song, ZW Zhao, XF Huang… - Mathematical …, 2019 - europepmc.org
Background: An increasing number of patients with advanced non-small cell lung cancer
(NSCLC) have a poor prognosis and develop progressive disease after receiving …
(NSCLC) have a poor prognosis and develop progressive disease after receiving …